Humana earnings release, July 29, 2026

Humana Inc (HUM) · Form 8-K, Item 2.02 · Filed · SEC filing

FOR MORE INFORMATION CONTACT:

Mark Taylor

Humana Corporate Communications

(317) 753-0345 e-mail: MTaylor108@humana.com

Humana Reports Second Quarter 2026 Financial Results;

Affirms Full Year 2026 Adjusted Financial Guidance

• Reports 2Q26 earnings per share (EPS) of $5.73 on a GAAP basis,

Adjusted EPS of $7.61; reports year to date (YTD) 2026 EPS of $15.55 on a GAAP basis, $17.91 on an Adjusted basis

• 2Q26 Insurance segment GAAP benefit ratio of 91.2 percent, in line with management's guidance of 'slightly above 91 percent'; affirms full year (FY) 2026 Insurance segment benefit ratio guidance of 92.75 percent, plus or minus 25 basis points

• Affirms FY 2026 Adjusted EPS guidance of 'at least $9.00'; while revising GAAP EPS guidance to

'at least $6.52' from the previous estimate of 'at least $8.36'

• Affirms FY 2026 individual Medicare Advantage (MA) membership growth of 'approximately 25 percent' over 2025; driven by new sales and improved retention from the company's customer-led benefit strategy and changes to its customer service approach

• Continued strategic expansion of the company's CenterWell and Medicaid footprints

◦ YTD growth of 130,900 patients, or 27 percent, in CenterWell Senior Primary Care

◦ Broadened Illinois Medicaid footprint with the award of a statewide Illinois Medicaid managed care contract expected to go live in January 2027; Humana was the only new entrant awarded along with five incumbents

• Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

LOUISVILLE, KY (July 29, 2026) – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended June 30, 2026 (2Q26) versus the quarter ended June 30, 2025 (2Q25) and for the six months ended June 30, 2026 (YTD 2026) versus the six months ended June 30, 2025 (YTD 2025) as noted in the tables below.¹

Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-year quarterly and YTD comparisons.

"The first half of the year went well, and we're right where we said we'd be at Investor Day last year," said Humana President and CEO Jim Rechtin. "When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve.”

FY 2026 Earnings Guidance

Humana revises its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) to 'at least $6.52' from 'at least $8.36', while affirming its Adjusted EPS guidance of 'at least $9.00'. The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation.

Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.

Detailed Press Release

Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website).²

Conference Call

Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time today to discuss its financial results for the quarter and the company’s expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).

A webcast of the 2Q26 earnings call may be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/.

If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https://register-conf.media-server.com/register/BI18085d824058461aa3c6b8b2af27cb40.

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.

The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.

Footnotes... (truncated)ect to inherent limitations and may differ from similarly titled measures used by other companies.

All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

Financial statements

Income Statement

YTD 2026 (a) (in millions)

2Q26 (a)2Q25 (a)YTD 2026 (a)YTD 2025 (a)
Revenues39,14031,09477,19962,031
Benefit ratio91.289.990.388.7
Operating cost ratio7.18.37.28.3
Income from operations8207662,2552,340
Income from operations - Adjusted (non-GAAP)8247702,2632,349

Income Statement (in millions)

2Q262Q25YTD 2026YTD 2025
Revenues6,7905,53712,89010,632
Operating cost ratio92.492.793.492
Income from operations466344755736
Income from operations - Adjusted (non-GAAP) (d)514404852855

Income Statement

Humana Inc. FY 2026 Guidance - As of July 29, 2026

Humana Inc. FY 2026 Guidance - As of July 29, 2026 – no changes from initial FY 2026 guidance provided as of February 11, 2026, with the exception of GAAP EPS – Diluted earnings per common share (EPS) – GAAP: 'at least $6.52' (previously 'at least $8.36') – Non-GAAP: 'at least $9.00' – Total Revenues – At least $160 billion – At least $155 billion – At least $25 billion – Change in year-end medical membership from prior year-end – growth of approximately 25 percent – growth of approximately 150,000 – growth of approximately 1,000,000 – growth of 25,000 to 100,000
Benefit Ratio Insurance segmentGAAP: 92.75% +/- 25 bps
Operating Cost Ratio ConsolidatedGAAP: 10.0% +/- 25 bps
Segment ResultsInsurance segment income from operationsGAAP: approximately breakeven
Segment ResultsCenterWell segment income from operationsGAAP: $1.3B to $1.8B Non-GAAP: $1.5B to $2.0B
Segment ResultsEffective Tax RateGAAP: approximately 25.5%
Segment ResultsWeighted Avg. Share Count for Diluted EPSapproximately 121 million
Segment ResultsCash flows from operationsGAAP: $2.5 billion to $2.9 billion
Segment ResultsCapital expendituresapproximately $650 million

Income Statement

For the three months ended June 30, — Dollars in millions, except per common share results

For the three months ended June 30, – 2026For the three months ended June 30, – 2025For the six months ended June 30, – 2026For the six months ended June 30, – 2025
Revenues:Premiums38,83430,71676,54361,230
Revenues:Services1,7801,4003,4572,734
Revenues:Net investment income253272515536
Revenues:Total revenues40,86732,38880,51564,500
Operating expenses:Benefits35,37027,56569,07754,100
Operating expenses:Operating costs3,9783,5478,0026,927
Operating expenses:Depreciation and amortization159178322361
Operating expenses:Total operating expenses39,50731,29077,40161,388
Operating expenses:Income from operations1,3601,0983,1143,112
Operating expenses:Interest expense197157390317
Operating expenses:Other expense, net211200177363
Operating expenses:Income before income taxes and equity in net losses9527412,5472,432
Operating expenses:Provision for income taxes238179633585
Operating expenses:Equity in net losses (A)-21-19-37-62
Operating expenses:Net income6935431,8771,785
Operating expenses:Net loss attributable to noncontrolling interests1234
Operating expenses:Net income attributable to Humana6945451,8801,789
Operating expenses:Basic earnings per common share5.784.5215.6414.83
Operating expenses:Diluted earnings per common share5.734.5115.5514.81
Operating expenses:Shares used in computing basic earnings per common share (000’s)120,066120,539120,199120,602
Operating expenses:Shares used in computing diluted earnings per common share (000’s)121,135120,745120,893120,794

Income Statement

Eliminations/ Corporate — In millions

InsuranceCenterWellEliminations/ CorporateConsolidated
Revenues—external customers premiums:Individual Medicare Advantage28,87528,875
Revenues—external customers premiums:Group Medicare Advantage2,8512,851
Revenues—external customers premiums:Medicare stand-alone PDP2,9952,995
Revenues—external customers premiums:Total Medicare34,72134,721
Revenues—external customers premiums:State-based contracts and other3,5013,501
Revenues—external customers premiums:Specialty benefits268268
Revenues—external customers premiums:Medicare Supplement344344
Revenues—external customers premiums:Total premiums38,83438,834
Services revenue:Home solutions360360
Services revenue:Primary care839839
Services revenue:Pharmacy solutions382382
Services revenue:Military services and other199199
Services revenue:Total services revenue1991,5811,780
Services revenue:Total revenues—external customers39,0331,58140,614
Services revenue:Intersegment revenues25,209-5,211
Services revenue:Net investment income105148253
Services revenue:Total revenues39,1406,790-5,06340,867
Operating expenses:Benefits35,423-5335,370
Operating expenses:Operating costs2,7586,276-5,0563,978
Operating expenses:Depreciation and amortization13948-28159
Operating expenses:Total operating expenses38,3206,324-5,13739,507
Operating expenses:Income from operations820466741,360
Operating expenses:Benefit ratio91.291.1
Operating expenses:Operating cost ratio7.192.49.8

Income Statement

Eliminations/ Corporate — In millions

InsuranceCenterWellEliminations/ CorporateConsolidated
Revenues—external customers premiums:Individual Medicare Advantage22,76422,764

Income Statement

Eliminations/ Corporate — In millions

InsuranceCenterWellEliminations/ CorporateConsolidated
Revenues—external customers premiums:Individual Medicare Advantage57,12757,127
Revenues—external customers premiums:Group Medicare Advantage5,7625,762
Revenues—external customers premiums:Medicare stand-alone PDP5,6125,612
Revenues—external customers premiums:Total Medicare68,50168,501
Revenues—external customers premiums:State-based contracts and other6,8336,833
Revenues—external customers premiums:Specialty benefits536536
Revenues—external customers premiums:Medicare Supplement673673
Revenues—external customers premiums:Total premiums76,54376,543
Services revenue:Home solutions703703
Services revenue:Primary care1,6271,627
Services revenue:Pharmacy solutions679679
Services revenue:Military services and other4462448
Services revenue:Total services revenue4463,00923,457
Services revenue:Total revenues—external customers76,9893,009280,000
Services revenue:Intersegment revenues39,881-9,884
Services revenue:Net investment income207308515
Services revenue:Total revenues77,19912,890-9,57480,515
Operating expenses:Benefits69,121-4469,077
Operating expenses:Operating costs5,54212,038-9,5788,002
Operating expenses:Depreciation and amortization28197-56322
Operating expenses:Total operating expenses74,94412,135-9,67877,401
Operating expenses:Income from operations2,2557551043,114
Operating expenses:Benefit ratio90.390.2
Operating expenses:Operating cost ratio7.293.410

Income Statement

Eliminations/ Corporate — In millions

InsuranceCenterWellEliminations/ CorporateConsolidated
Revenues—external customers premiums:Individual Medicare Advantage45,44545,445
Revenues—external customers premiums:Group Medicare Advantage4,5824,582
Revenues—external customers premiums:Medicare stand-alone PDP3,1693,169
Revenues—external customers premiums:Total Medicare53,19653,196
Revenues—external customers premiums:State-based contracts and other7,0287,028
Revenues—external customers premiums:Specialty benefits490490
Revenues—external customers premiums:Medicare Supplement516516
Revenues—external customers premiums:Total premiums61,23061,230
Services revenue:Home solutions695695
Services revenue:Primary care982982
Services revenue:Pharmacy solutions599599
Services revenue:Military services and other458458
Services revenue:Total services revenue4582,2762,734
Services revenue:Total revenues—external customers61,6882,27663,964
Services revenue:Intersegment revenues28,356-8,358
Services revenue:Net investment income341195536
Services revenue:Total revenues62,03110,632-8,16364,500
Operating expenses:Benefits54,296-19654,100
Operating expenses:Operating costs5,0929,777-7,9426,927
Operating expenses:Depreciation and amortization303119-61361
Operating expenses:Total operating expenses59,6919,896-8,19961,388
Operating expenses:Income from operations2,340736363,112
Operating expenses:Benefit ratio88.788.4
Operating expenses:Operating cost ratio8.39210.8

Balance Sheet

December 31, — Dollars in millions, except share amounts

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents6,8934,200
Current assets:Investment securities16,97815,703
Current assets:Receivables, net5,6953,270
Current assets:Other current assets10,5209,560
Current assets:Total current assets40,08632,733
Current assets:Property and equipment, net2,0982,231
Current assets:Long-term investment securities650493
Current assets:Equity method investments627638
Current assets:Goodwill10,4859,686

Cash Flow

For the six months ended June 30, — Dollars in millions

For the six months ended June 30, – 2026For the six months ended June 30, – 2025
Cash flows from operating activitiesNet income1,8771,785
Adjustments to reconcile net income to net cash provided by operating activities:Losses (gains) on investment securities, net26-13
Adjustments to reconcile net income to net cash provided by operating activities:Equity in net losses3762
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation116110
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation363396
Adjustments to reconcile net income to net cash provided by operating activities:Amortization1930
Adjustments to reconcile net income to net cash provided by operating activities:Impairment of property and equipment2514
Adjustments to reconcile net income to net cash provided by operating activities:Impairment of indefinite-lived intangible assets32
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Receivables-2,392-1,800
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Other assets-902-658
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Benefits payable2,909620
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Other liabilities1,2411,010
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Unearned revenues-10714
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Other, net8
Changes in operating assets and liabilities, net of effect of businesses acquired and disposed:Net cash provided by operating activities3,2201,602
Cash flows from investing activitiesAcquisitions, net of cash acquired-930-1
Cash flows from investing activitiesProceeds from sale of business, net40
Cash flows from investing activitiesPurchases of property and equipment, net-253-209
Cash flows from investing activitiesChanges in securities lending collateral receivable-64-48
Cash flows from investing activitiesPurchases of investment securities-4,230-1,941
Cash flows from investing activitiesProceeds from maturities of investment securities1,5611,617
Cash flows from investing activitiesProceeds from sales of investment securities1,0501,243
Cash flows from investing activitiesNet cash (used in) provided by investing activities-2,826661
Cash flows from financing activitiesReceipts (payments) from contract deposits, net547-579
Cash flows from financing activitiesProceeds from issuance of notes, net9901,481
Cash flows from financing activitiesRepayments of notes-281-771
Cash flows from financing activitiesProceeds (repayments) from issuance of commercial paper, net1,300-5
Cash flows from financing activitiesDebt issue costs-16-5
Cash flows from financing activitiesChange in book overdraft45-105
Cash flows from financing activitiesCommon stock repurchases-108-109
Cash flows from financing activitiesDividends paid-214-214
Cash flows from financing activitiesChange in securities lending payable6448
Cash flows from financing activitiesChange in rebate factor payable-123
Cash flows from financing activitiesOther-28-62
Cash flows from financing activitiesNet cash provided by (used in) financing activities2,299-444
Cash flows from financing activitiesIncrease in cash and cash equivalents2,6931,819
Cash flows from financing activitiesCash and cash equivalents at beginning of period4,2002,221
Cash flows from financing activitiesCash and cash equivalents at end of period6,8934,040
Full release

(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.

• Amortization associated with identifiable intangibles -

Since amortization varies based on the size and timing of acquisition activity, management believes the exclusion of this non-cash expense provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release,

GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment:

• Put/call valuation adjustments associated with the company’s non-consolidating minority interest investments -

These non-cash amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business performance. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.

• Value creation initiatives -

These charges relate to the company's multi-year transformation program, as approved by management with defined scope and milestones. The intent of the program is to re-align the company’s cost structure, operating model, and technology footprint with evolving market conditions. These costs primarily include severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. These charges were recorded at the corporate level and not allocated to the segments. The company has consistently applied this adjustment across³ all periods. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.

• Impairment charges

-

During 2Q26, the company recognized non-cash impairment charges related to investments for which the company held minority ownership interests that were deemed to be unrecoverable based on recent market activity. In 2Q25, the company recognized non-cash impairment charges related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. These charges were recorded at the corporate level and not allocated to the segments. For 2Q26 and YTD 2026, GAAP measures affected include consolidated pretax results, EPS, and consolidated revenues. For 2Q25 and YTD 2025, GAAP measures affected included consolidated pretax results, EPS, and the consolidated operating cost ratio. The FY 2025 GAAP EPS measure was also impacted by this adjustment.

• Cumulative net tax impact -

This adjustment represents the cumulative net impact of the corresponding tax benefit or expense at the applicable marginal rate related to the aforementioned items excluded from the applicable GAAP measures. For FY 2025, the tax adjustment reflects the impact of the loss on sale of business, which exceeded the book loss. The related tax benefit from the loss on sale of business is realizable via capital loss carryback. The tax impact of the aforementioned items differs from the statutory rates due to jurisdictional mix, limitations on deductibility, and other factors. The cumulative tax impact is not intended to represent a normalized effective tax rate or expected future tax outcomes. For all periods presented in this earnings release,

EPS is the sole GAAP measure affected.

The following adjustments impact only the FY 2025 GAAP EPS shown within this release on page 2.

• Impact of exit of employer group commercial medical products business -

These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.

• Settlement of certain litigation expenses -

These charges relate to expenses the company recognized in connection with a discrete legal matter. The nature and magnitude of this settlement are not indicative of the company’s ongoing operations.

• Loss on sale of business -

This discrete disposition is not part of the company's ordinary course operations and the impacts recognized from the disposal do not reflect core operational performance. The loss primarily reflects the difference between the carrying value and proceeds at the time of sale.

In addition to the reconciliations shown on pages 1 and 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

Revenues

Operating cost ratio⁴

Insurance Segment - Income from operations

(b) FY 2026 GAAP EPS guidance and FY 2026 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that have not yet been recognized and cannot currently be reasonably estimated at this time.

Cautionary Statement

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “assumes,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements.... (truncated)re not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

• If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.

• If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company’s business may be materially adversely affected.

• The number of Humana’s Medicare Advantage plans rated 4-star or higher significantly declined in 2025. Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, and on October 14, 2025, the Court issued a decision rejecting Humana's challenge. Although the company has appealed that decision, there can be no assurances that it will ultimately prevail in the lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company’s revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years.

• If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems (including systems powered by or incorporating artificial intelligence (AI) or machine learning (ML)), or to protect Humana’s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or⁵ prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company’s business may be materially adversely affected.

• Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company’s cost of doing business.

• As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company’s Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.

• ... (truncated)reasing the company’s expenses associated with a non-deductible health insurance industry fee and other assessments); the company’s financial position (including the company’s ability to maintain the value of its goodwill); and the company’s cash flows.

• Humana’s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company’s results of operations, financial position, and cash flows.

• If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.

• Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company’s success, and its failure to do so could adversely affect the Company’s businesses, operating results and/or future performance.

• Humana’s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.

• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.

• Humana’s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.

• Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.⁶

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

• Form 10-K for the year ended December 31, 2025;

• Form 10-Q for the quarter ended March 31, 2026; and

• Form 8-Ks filed during 2026.

About Humana

Humana (NYSE: HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Humana earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.